Welcome to our dedicated page for APOLLOMICS news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. (APLM) is a clinical-stage biopharmaceutical company pioneering novel combination therapies for treatment-resistant cancers. This page consolidates all official news, press releases, and regulatory filings related to the company’s oncology research and strategic initiatives.
Investors and industry professionals will find timely updates on clinical trial results, regulatory milestones, and partnership announcements. The resource prioritizes APLM’s advancements in c-Met inhibitors, E-selectin antagonists, and immuno-oncology combinations, providing stakeholders with a comprehensive view of the company’s progress.
Key categories include updates on Phase I-III trials, FDA communications, intellectual property developments, and financial performance reports. All content is sourced directly from Apollomics’ disclosures to ensure accuracy and compliance.
Bookmark this page for streamlined access to APLM’s latest developments in precision oncology. Check back regularly for real-time updates on pipeline advancements and corporate news shaping the future of cancer treatment.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 13, 2025 to meet the $1.00 per share minimum bid price for its Ordinary Shares. This extension follows a previous notice of non-compliance received on January 16, 2024.
To regain compliance, Apollomics must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before the deadline. If unsuccessful, the company may face delisting, with an option to appeal to a Nasdaq Hearings Panel. Apollomics is actively monitoring its stock price and exploring options to meet the requirement, though success is not guaranteed.
Apollomics (Nasdaq: APLM) announced a revised strategic focus on the clinical development of vebreltinib for NSCLC patients with Met Amplification mutations and significant changes in its executive leadership. The SPARTA Phase 2 trial will concentrate on this high-need patient population. Co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., will transition to consulting roles in August. These changes are part of a broader cost-reduction strategy expected to cut operating expenses by over 50% and extend funding until Q3 2025.
Apollomics aims to generate additional clinical data to support regulatory submissions, with updates anticipated in 2024 and 2025. The departures of key executives are aligned with the company's resource needs and focus on maximizing the efficient use of capital.
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6.31 months median overall survival (OS) in glioblastoma patients with PTPRZ1-MET Fusion gene. No new safety concerns were identified. Apollomics aims to continue advancing vebreltinib's clinical development.
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
FAQ
What is the current stock price of APOLLOMICS (APLM)?
What is the market cap of APOLLOMICS (APLM)?
